Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis. | I. Gardner

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects | O. Hatley

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

The relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS | K. Dooley

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

A translational modelling and simulations approach to exploit pre-clinical tuberculosis data | S. Wicha

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling | R. Rajoli

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSB

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifapentine plus Isoniazid Eradicates Mycobacterium tuberculosis among Rhesus Macaques with Latent TB Infection | H. Blumberg

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

High drug tolerance of Mycobacterium tuberculosis in caseum | J. Sarathy

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Exploration of Non-Replicating Mycobacterium Tuberculosis In Vitro System Through Mathematical Modelling | A. Schipani

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

A model-based analysis to describe bedaquiline’s exposure-response relationship and predict the impact of drug-drug interactions | E. Svensson

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Population Pharmacokinetics of AZD5847 in Adults with Pulmonary Tuberculosis | C. Peloquin

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin | R. Svensson

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Impact on: Adherence/tolerability - Ian McGowan, MB, ChB, DPhil, MD, FRCP

European HIV Clinical Forum 2016

Impact on: Virology/Resistance - Daniel Kuritzkes, MD

European HIV Clinical Forum 2016

A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Pos. ART-exp. Patients with Stable Viral Suppression- Alberto Borghetti

European HIV Clinical Forum 2016

Impact on: Pharmacology – penetration to sanctuary sites and drug-drug interactions - Courtney Fletcher, PharmD

European HIV Clinical Forum 2016

Virological failure even at low levels of viremia can be associated to integrase strand-transfer inhibitors resistance in HIV-1 infected patients - Benet Garrabé

European HIV Clinical Forum 2016

French National survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS AC11 virology network) - Vincent Calvez

European HIV Clinical Forum 2016

An Italian case of transmitted integrase inhibitor resistance in a drug-naïve patient: a refined analysis by ultra-deep-454 pyrosequencing - Ada Bertoli

European HIV Clinical Forum 2016

Clinical Case Presentations – How to manage drug - drug interactions - the practice - Anna Maria Geretti, MD, PhD, FRCPath

European HIV Clinical Forum 2016

Clinical Utility of Integrase Inhibitors during pregnancy - Saye Khoo, MD, PhD

European HIV Clinical Forum 2016

Virological response of HIV-infected-patients virologically-suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score - Diane Descamps

European HIV Clinical Forum 2016

Lamivudine plus either Atazanavir/ritonavir, Darunavir/ritonavir or Dolutegravir as switch strategies in HIV-positive, virologically-suppressed patients: a comparison - Alberto Borghetti

European HIV Clinical Forum 2016